Outcome of Patients Treated With IABP

Coronary Artery Disease Clinical Trial

Official title:

Outcome of Patients Treated With Intra Aortic Balloon Pump

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04405856
• Other study ID #: IABP-Jsph
• Status: Recruiting
• Start date: February 1, 2012
• Est. completion date: December 31, 2025

Study information

• Verified date: May 2020
• Source: Nanjing Medical University
• Contact: Hong Liu, MD
• Phone: 18801281613
• Email: DR.HONGLIU[@]FOXMAIL.COM
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Intra-Aortic Balloon Pumps (IABP) is a widely used and effective left ventricular adjuvant therapy. IABP is an inflatable device placed in the aorta that inflates with diastole and deflates with systole. The aim of this study is to investigate the outcome of patients treated With IABP, and to evaluate the short-term and long-term outcomes of patients with IABP.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1000
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2025
• Gender: All
• Age group: 1 Year to 100 Years

Eligibility

Inclusion Criteria:

• Patients receiving IABP for circulatory support

Exclusion Criteria:

• Refusal of consent

Related Conditions & MeSH terms

• Acute Coronary Syndrome
• Cardiac Output, Low
• Cardiogenic Shock
• Coronary Artery Disease
• Heart Failure
• Left Ventricular Dysfunction
• Low Cardiac Output Syndrome
• Post-cardiac Surgery
• Shock, Cardiogenic
• Syndrome
• Ventricular Dysfunction
• Ventricular Dysfunction, Left

Intervention

Device:
• Intra Aortic Balloon Pump
Intra Aortic Balloon Pump (IABP) is a circulatory mechanical support device, placed in descending aorta, distally from left subclavian artery and proximally from renal artery. IABP works with counterpulsation concept, synchronized with heart cycle.

Locations

Country	Name	City	State
China	The first affiliated hospital of nanjing medical university	Nanjing	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
Nanjing Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	All-cause mortality		30 days after IABP implantation
Secondary	All-cause mortality		3 months after IABP implantation